| Original language | English (US) |
|---|---|
| Pages (from-to) | 2876-2877 |
| Number of pages | 2 |
| Journal | Journal of the American College of Cardiology |
| Volume | 63 |
| Issue number | 25 PART A |
| DOIs | |
| State | Published - Jul 1 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 63, No. 25 PART A, 01.07.2014, p. 2876-2877.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing
T2 - Insights from the NCDR PINNACLE registry
AU - Hira, Ravi S.
AU - Kennedy, Kevin
AU - Jneid, Hani
AU - Alam, Mahboob
AU - Basra, Sukhdeep S.
AU - Petersen, Laura A.
AU - Ballantyne, Christie M.
AU - Nambi, Vijay
AU - Chan, Paul S.
AU - Virani, Salim S.
N1 - Funding Information: Please note: Dr. Alam has been a member of the advisory board for AstraZeneca. Dr. Petersen has received grant/research support from the National Institutes of Health ( R01 HL0791731 ) and the Houston VA HSR&D Center of Excellence ( HFP9O-020 ). Dr. Ballantyne has received grant/research support (all significant [>$10,000] and all paid to institution, not individual) from Abbott, Amarin, Amgen, Eli Lilly, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo, the National Institutes of Health, and the American Heart Association; she has also served as a consultant for Abbott, Aegerion, Amarin, Amgen, Arena, Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck, Novartis, Pfizer, Resverlogix, Regeneron, Roche, and Sanofi-Synthelabo; and on the speakers' bureau for Abbott. Dr. Nambi was a national monitor for a study sponsored by Anthera Inc.; a co-investigator on a provisional patent filed by Baylor College of Medicine, Roche Diagnostics, on the use of biomarkers in heart failure prediction; and involved in a research collaboration with GE and Tomtec. Dr. Virani has received grant/research support in the form of a Department of Veterans Affairs Health Services Research and Development Career Development Award (09-028) and an American Diabetes Association Clinical Science and Epidemiology Award (1-14-CE-44). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
PY - 2014/7/1
Y1 - 2014/7/1
UR - http://www.scopus.com/inward/record.url?scp=84903142657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903142657&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2014.04.011
DO - 10.1016/j.jacc.2014.04.011
M3 - Letter
C2 - 24814485
AN - SCOPUS:84903142657
SN - 0735-1097
VL - 63
SP - 2876
EP - 2877
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 25 PART A
ER -